 FLORHAM PARK, N.J., Sept. 07, 2021 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB, a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference. 